Avishai Levy


AvishayAvishai Levy has over 20 years of experience in senior management positions. His past roles include CEO of The Galilee Research Institute, a 300+ employees multidisciplinary applied research Institute, CEO of Proteologics Ltd, a public drug discovery company which among its shareholders were Teva and GSK, and a co-facilitator and board member of Immpact Bio, which develops disruptive CAR-T therapies and among its shareholders are J&J, Takeda Ventures, Orbimed, and Novartis Venture Fund. Mr. Levy’s academic record includes Executive LL.M from Northwestern law school, Chicago IL.